Drugs that contain Angiotensin Ii Acetate

1. List of Giapreza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10548943 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(6 years from now)

US9867863 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(6 years from now)

US10500247 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(6 years from now)

US10335451 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(6 years from now)

US9572856 LA JOLLA PHARMA Method of treating low blood pressure
Jul, 2031

(8 years from now)

US11096983 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

US10028995 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

US10493124 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

US9220745 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

US11219662 LA JOLLA PHARMA Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II
Jan, 2037

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 21, 2022

NCE-1 date: December, 2021

Market Authorisation Date: 21 December, 2017

Treatment: Increasing blood pressure with a rate of about 20 ng/kg/min to about 40 ng/kg/min angiotensin ii in a human subject having septic shock; Increasing blood pressure with an initial rate of about 20 ng/kg/min angiotensin ii in a human subject having septic shock, and titrating the rate up.; Treating refractory hypotension with about 5 ng/kg/min to about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor; Treating low blood pressure with angiotensin ii with an initial rate of about 5 ng/kg/min to about 20 ng/kg/min in a subject having refractory hypotension or severe hypotension, and titrating the rate up; Treating low blood pressure with angiotensin ii with an initial rate of about 5 ng/kg/min to about 20 ng/kg/min in a subject having refractory hypotension or severe hypotension; Treating hypotension with about 20 ng/kg/min to about 40 ng/kg/min angiotensin ii in a human subject having septic shock; Treating refractory hypotension with about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor; Treating distributive shock with angiotensin ii; Treating septic shock with angiotensin ii; Maintaining mean arterial pressure of about 65 mmhg or above with about 1 ng/kg/min to about 40 ng/kg/min angiotensin ii in hypotensive patients treated with vasopressin or a vasopressin analogue and reducing vasopressin or vasopressin analogue use; Treating low blood pressure with angiotensin ii at an initial rate of about 20 ng/kg/min and titrating down to achieve and/or maintain a map of about 65 mm hg or above; Maintaining mean arterial pressure of about 65 mmhg or higher with angiotensin ii in shock patients treated with catecholamines and reducing catecholamine use; Treating high output shock with angiotensin ii by increasing mean arterial pressure in patients treated with catecholamines and reducing catecholamine use; Treating hypotension with angiotensin ii in a patient receiving an angiotensin converting enzyme inhibitor

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of GIAPREZA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in